What are Generate Biomedicines, Inc. 's total assets?

Generate Biomedicines, Inc. (GENB) holds $625.7M in total assets.

How much debt does Generate Biomedicines, Inc. have?

Generate Biomedicines, Inc. carries $65.6M in total debt against $514.8M of shareholders' equity, a debt-to-equity ratio of 0.13.

How much cash does Generate Biomedicines, Inc. have?

Generate Biomedicines, Inc. holds $160.6M in cash and equivalents.

Can Generate Biomedicines, Inc. cover its short-term obligations?

Its current ratio is 9.17 — current assets exceed current liabilities.

Where does Generate Biomedicines, Inc. 's balance sheet data come from?

Every line is extracted from Generate Biomedicines, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Generate Biomedicines, Inc. GENB Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q1 '25
Cash and cash equivalents	$160.58M+32.0%	$121.65M-44.9%	$220.61M—
Short-term investments	$356.07M+257%	$99.85M—	——
Restricted cash	$0-100%	$339K—	——
Prepaid expenses and other current assets	$18.75M+49.7%	$12.53M+355%	$2.76M—
Total current assets	$535.39M+128%	$234.37M—	——
Property and equipment, net	$27.84M-4.5%	$29.15M—	——
Total assets	$625.74M+89.5%	$330.18M—	——
Accounts payable	$7.62M+98.5%	$3.84M+743%	-$597K—
Operating lease liabilities, current	$10.38M-3.0%	$10.7M—	——
Finance Lease Liability, Current	$3.88M-9.9%	$4.31M—	——
Total current liabilities	$58.39M-29.0%	$82.2M—	——
Operating lease liabilities, non-current	$49.09M-3.0%	$50.61M—	——
Finance lease liabilities	$2.22M-23.6%	$2.91M—	——
Other non-current liabilities	$0-100%	$116K—	——
Total liabilities	$110.94M-21.6%	$141.55M—	——
Retained earnings	-$737.74M-9.1%	-$676.29M—	——
Accumulated other comprehensive income (loss)	$24K-77.4%	$106K—	——
Total stockholders' equity	$514.8M+184%	-$615.97M-30.8%	-$471M-8.4%
Total liabilities and stockholders' equity	$625.74M+89.5%	$330.18M—	——
Short- term Investments	$356.07M+257%	$99.85M—	——
Deferred Tax Assets and Other Non-Current Assets	$4.75M-30.3%	$6.81M—	——
Net Investment in Lease	$57.77M-3.5%	$59.86M—	——
Operating lease right-of-use assets	$57.77M-3.5%	$59.86M—	——
Other non-current assets	$4.75M-30.3%	$6.81M—	——
Operating Lease Right-of-Use Assets in Other Assets	$57.77M-3.5%	$59.86M—	——
Software and Technology Licenses, Net	$4.75M-30.3%	$6.81M—	——
Accrued Expenses And Other Liabilities Current	$19.27M-54.3%	$42.16M—	——
Deferred income	$17.24M-18.6%	$21.19M—	——
Deferred income	$1.24M-72.6%	$4.51M—	——
Total debt	$65.57M-4.3%	$68.53M—	——
Additional paid-in capital	$1.25B+1,981%	$60.19M—	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$128K+288%	$33K—	——
Current maturities of long-term debt	$3.88M-9.9%	$4.31M—	——
Noncontrolling interests in subsidiaries	$0+100%	-$7.23M—	——
Warrant To Purchase Convertible Preferred Stock	$0-100%	$1.21M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Generate Biomedicines, Inc. 's total assets?: Generate Biomedicines, Inc. (GENB) holds $625.7M in total assets.
How much debt does Generate Biomedicines, Inc. have?: Generate Biomedicines, Inc. carries $65.6M in total debt against $514.8M of shareholders' equity, a debt-to-equity ratio of 0.13.
How much cash does Generate Biomedicines, Inc. have?: Generate Biomedicines, Inc. holds $160.6M in cash and equivalents.
Can Generate Biomedicines, Inc. cover its short-term obligations?: Its current ratio is 9.17 — current assets exceed current liabilities.
Where does Generate Biomedicines, Inc. 's balance sheet data come from?: Every line is extracted from Generate Biomedicines, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.